-Early highly effective arm: ocrelizumab, natalizumab, alemtuzumab, rituximab)- Escalation arm: any other approved MS therapy (beta interferon, glatiramer acetate, teriflunomide, fingolimod, dimethyl fumarate)- No intervention. This evidence concerns the gene IFNB1 and myeloid sarcoma.